Monitoring and management of immune-related adverse events associated with programmed cell death protein-1 axis inhibitors in lung cancer

Oncologist

Volumn 22, Issue 1, 2017, Pages 70-80

  O’Kane, Grainne M ^a   Labbé, Catherine ^a   Doherty, Mark K ^a   Young, Kelvin ^a   Albaba, Hamzeh ^a   Leighl, Natasha B ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Immune related adverse events; Immunotherapy; Lung cancer; Programmed cell death protein 1; Programmed death ligand 1; Toxicities

Indexed keywords

ANTINEOPLASTIC AGENT; ATEZOLIZUMAB; AVELUMAB; DURVALUMAB; INFLIXIMAB; IPILIMUMAB; LOPERAMIDE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; NIVOLUMAB; PEMBROLIZUMAB; PREDNISONE; PROGRAMMED CELL DEATH PROTEIN 1 INHIBITOR; PROGRAMMED DEATH 1 RECEPTOR; TICILIMUMAB; UNCLASSIFIED DRUG; CD274 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1;

ADRENAL INSUFFICIENCY; ARTHRALGIA; ARTICLE; ASTHENIA; COLITIS; COMPUTER ASSISTED TOMOGRAPHY; DECREASED APPETITE; DIARRHEA; ENDOCRINE DISEASE; FATIGUE; FEVER; HUMAN; HYPERTHYROIDISM; HYPERTRANSAMINASEMIA; HYPOPHYSITIS; HYPOTHYROIDISM; LEUKOCYTOSIS; LIVER TOXICITY; LUNG CANCER; NAUSEA; NEUROLOGIC DISEASE; PANCREATITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SIGMOIDOSCOPY; SKIN TOXICITY; THORAX RADIOGRAPHY; THYROID DISEASE; ADVERSE DRUG REACTION; ANTAGONISTS AND INHIBITORS; CLASSIFICATION; DRUG EFFECTS; GENETICS; IMMUNOLOGY; LUNG TUMOR; MOLECULARLY TARGETED THERAPY; PATHOLOGY; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; B7-H1 ANTIGEN; CTLA-4 ANTIGEN; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PROGRAMMED CELL DEATH 1 RECEPTOR; SIGNAL TRANSDUCTION;

EID: 85011416481     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2016-0164     Document Type: Article

References (68)

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 4. 2016. Available at: https://www.nccn.org/professionals/physician_gls/f_guidelines_nojava.asp. Accessed March 18, 2016.
2. Champiat S, Lambotte O, Barreau E et al. Man-agement of immune checkpoint blockade dysimmu-netoxicities: A collaborative position paper. Ann Oncol 2016;27:559-574.
3. Rothenstein JM, Letarte N. Managing treatment-related adverse events associated with Alk inhibitors. Curr Oncol 2014;21:19-26.
4. Pardoll DM. The blockade of immune check-points in cancer immunotherapy. Nat Rev Cancer 2012;12:252-264.
5. Zhou ZJ, Zhan P, Song Y. PD-L1 over-expression and survival in patients with non-small cell lung can-cer: A meta-analysis. Transl Lung Cancer Res 2015;4: 203-208.
6. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373:123-135.
7. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015;373:1627-1639.
8. Herbst RS, Baas P, Kim DW et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-posi-tive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet 2016; 387:1540-1550.
9. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010;236:219-242.
10. Berman D, Korman A, Peck R et al. The develop-ment of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: The Bristol-Myers Squibb experience. Pharmacol Ther 2015;148:132-153.
11. Luhder F, Hoglund P, Allison JP et al. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J Exp Med 1998;187:427-432.
12. Wang HB, Shi FD, Li H et al. Anti-CTLA-4 anti-body treatment triggers determinant spreading and enhances murine myasthenia gravis. J Immunol 2001;166:6430-6436.
13. Perrin PJ, June CH, Maldonado JH et al. Block-ade of CD28 during in vitro activation of encephalito-genic T cells or after disease onset ameliorates experimental autoimmune encephalomyelitis. J Im-munol 1999;163:1704-1710.
14. Lee B, Wong A, Kee D et al. The use of ipilimu-mab in patients with rheumatoid arthritis and meta-static melanoma. Ann Oncol 2016;27:1174-1177.
15. Kyi C, Carvajal RD, Wolchok JD et al. Ipilimumab in patients with melanoma and autoimmune dis-ease. J Immunother Cancer 2014;2:35.
16. Pedersen M, Andersen R, Nørgaard P et al. Suc-cessful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and sys-temic autoimmune disease. Cancer Immunol Immun-other 2014;63:1341-1346.
17. Bostwick AD, Salama AK, Hanks BA. Rapid com-plete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis. J Immunother Can-cer 2015;3:19.
18. Johnson DB, Sullivan RJ, Ott PA et al. Ipilimu-mab therapy in patients with advanced melanoma and preexisting auto immune disorders. JAMA Oncol 2016;2:234-240.
19. Morales RE, Shoushtari AN, Walsh MM et al. Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation. J Immunother Cancer 2015;3:22.
20. Lipson EJ, Bodell MA, Kraus ES et al. Successful administration of ipilimumab to two kidney trans-plantation patients with metastatic melanoma. J Clin Oncol 2014;32:e69-e71.
21. Ranganath HA, Panella TJ. Administration of ipi-limumab to a liver transplant recipient with unre-sectable metastatic melanoma. J Immunother 2015; 38:211.
22. Spain L, Higgins R, Gopalakrishnan K et al. Acute renal allograft rejection after immune check-point inhibitor therapy for metastatic melanoma. Ann Oncol 2016;27:1135-1137.
23. El-Khoueiry AB, Melero I, Crocenzi TS et al. Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. J Clin Oncol 2015;33(suppl): ab-stract LBA101.
24. Davar D, Wilson M, Pruckner C et al. PD-1 blockade in advanced melanoma in patients with hepatitis C and/or HIV. Case Rep Oncol Med 2015; 2015:737389.
25. Kyi C, Hellmann MD, Wolchok JD et al. Oppor-tunistic infections in patients treated with immuno-therapy for cancer. J Immunother Cancer 2014;2:19.
26. Horvat TZ, Adel NG, Dang TO et al. Immune-related adverse events, need for systemic immuno-suppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 2015;33:3193-3198.
27. Leighl N, Ghandi L, Hellmann MD et al. Pem-brolizumab for NSCLC: immune-mediated adverse events and corticosteroid use. J Thorac Oncol 2015; 10:s233.
28. Weber JS, Antonia SJ, Topalian SL et al. Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis. J Clin Oncol 2015;33(suppl);9018a.
29. Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol 2010;37: 499-507.
30. O’Day SJ, Maio M, Chiarion-Sileni V et al. Effi-cacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: A multicenter single-arm phase II study. Ann Oncol 2010;21:1712-1717.
31. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012;30: 2691-2697.
32. Tarhini A. Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: The underlying mechanisms and clinical manage-ment. Scientifica (Cairo) 2013;2013:857519.
33. Lemech C, Arkenau HT. Novel treatments for metastatic cutaneous melanoma and the management of emergent oxicities. Clin Med Insights Oncol 2012;6:53-66.
34. Tarhini A, Lo E, Minor DR. Releasing the brake on the immune system: Ipilimumab in melanoma and other tumors. Cancer Biother Radiopharm 2010;25:601-613.
35. Villadolid J, Amin A. Immune checkpoint inhibi-tors in clinical practice: Update on management of immune-related toxicities. Transl Lung Cancer Res 2015;4:560-575.
36. Kleiner DE, Berman D. Pathologic changes in ipilimumab-related hepatitis in patients with meta-static melanoma. Dig Dis Sci 2012;57:2233-2240.
37. Naidoo J, Cunningham J, Woo KM et al. Pneu-monitis with anti-PD-1/PD-L1 therapy. Eur J Cancer 2015;51:S103.
38. Howell M, Lee R, Bowyer S et al. Optimal man-agement of immune-related toxicities associated with checkpoint inhibitors in lung cancer. Lung Cancer 2015;88:117-123.
39. Naidoo J, Page DB, Li BT et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint anti-bodies. Ann Oncol 2015;26:2375-2391.
40. Rizvi NA, Mazières J, Planchard D et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial. Lancet Oncol 2015;16:257-265.
41. Rossi E, Sgambato A, De Chiara G et al. Endocri-nopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer. Expert Rev Clin Pharmacol 2016;9:419-428.
42. Garber JR, Cobin RH, Gharib H et al. Clinical practice guidelines for hypothyroidism in adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Associa-tion. Endocr Pract 2012;18:988-1028.
43. Bristol-Myers Squibb YERVOY (ipilimumab). Serious and fatal immune-mediated adverse reac-tions—YERVOY Risk Evaluation and Mitigation Strat-egy (REMS). Abvailable at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125377s0000lbl.pdf. Accessed August 12, 2016.
44. Mahzari M, Liu D, Arnaout A et al. Immune checkpoint inhibitor therapy associated hypophysi-tis. Clin Med Insights Endocrinol Diabetes 2015;8: 21-28.
45. Joshi MN, Whitelaw BC, Palomar MT et al. Immune checkpoint inhibitor related hypophysitis and endocrine dysfunction: Clinical review. Clin Endocrinol (Oxf) 2016 [Epub ahead of print].
46. Marlier J, Cocquyt V, Brochez L et al. Ipilimu-mab, not just another anti-cancer therapy: Hypophy-sitis as side effect illustrated by four case-reports. Endocrine 2014;47:878-883.
47. Joseph RW, Cappel M, Goedjen B et al. Lichen-oid dermatitis in three patients with metastatic mel-anoma treated with anti-PD-1 therapy. Cancer Immunol Res 2015;3:18-22.
48. Naidoo J, Schindler K, Querfeld C et al. Auto-immune bullous skin disorders with immune check-point inhibitors targeting PD-1 and PD-L1. Cancer Immunol Res 2016;4:383-389.
49. Carlos G, Anforth R, Chou S et al. A case of bul-lous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab. Melanoma Res 2015;25:265-268.
50. Larkin J, Hodi FS, Wolchok JD. Combined nivolu-mab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:1270-1271.
51. Khoja L, Maurice C, Chappell M et al. Eosino-philic fasciitis and acute encephalopathy toxicity from pembrolizumab treatment of a patient with metastatic melanoma. Cancer Immunol Res 2016;4: 175-178.
52. Eggermont AM, Chiarion-Sileni V, Grob JJ et al. Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial. J Clin Oncol 2014;32:5s(LBA9008a).
53. Wilgenhof S, Neyns B. Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient. Ann Oncol 2011;22:991-993.
54. Goldberg SB, Gettinger SN, Mahajan A et al. Activity and safety of pembrolizumab in patients with metastatic non-small cell lung cancer with untreated brain metastases. J Clin Oncol 2015;33 (suppl):8035.
55. Kluger HM, Goldberg SB, Sznol M et al. Safety and activity of pembrolizumab in melanoma patients with untreated brain metastases. J Clin Oncol 2015;33(suppl):9009.
56. Yushak ML, Chiang VL, Kluger HM. Clinical trials in melanoma patients with brain metastases. Pig-ment Cell Melanoma Res 2015;28:741-743.
57. Knisely JP, Yu JB, Flanigan J et al. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg 2012;117:227-233.
58. Cohen JV, Kluger HM. Systemic immunother-apy for the treatment of brain metastases. Front Oncol 2016;6:49.
59. Cohen JV, Alomari AK, Vortmeyer AO et al. Mel-anoma brain metastasis pseudoprogression after pembrolizumab treatment. Cancer Immunol Res 2016;4:179-182.
60. Doherty MK, Jao K, Shepherd FA et al. Central nervous system pseudoprogression in a patient treated with PD-1 checkpoint inhibitor. J Thorac Oncol 2015;10:e100-e101.
61. Zhuang H, Yuan X, Zheng Y et al. A study on the evaluation method and recent clinical efficacy of bevacizumab on the treatment of radiation cerebral necrosis. Sci Rep 2016;6:24364.
62. Besse B, Johnson M, Janne PA et al. 16LBA Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung can-cer (NSCLC). Eur J Cancer 2015;51:s717-s718.
63. Fehrenbacher L, Spira A, Ballinger M et al. Ate-zolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POP-LAR): A multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016;387:1837-1846.
64. Gulley JL, Spigel DR, Kelly K et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: A phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy. J Clin Oncol 2015;33(suppl):8034a.
65. Gulley JL, Rajan A, Spigel DR et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or recurrent non-small-cell lung can-cer progressing after platinum-based chemotherapy: A phase Ib trial. Eur J Cancer 2015;51:3090.
66. Rizvi NA, Brahmer JR, Ou SH et al. Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2015;33(suppl):8032a.
67. Antonia S, Goldberg SB, Balmanoukian A et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: A mul-ticentre, phase 1b study. Lancet Oncol 2016;17:299-308.
68. Hellman MD, Gettinger SN, Goldman JW et al. CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC. J Clin Oncol 2016;34(suppl): 3001.